| Product NDC: | 0179-0096 |
| Proprietary Name: | RESCRIPTOR |
| Non Proprietary Name: | delavirdine mesylate |
| Active Ingredient(s): | 200 mg/1 & nbsp; delavirdine mesylate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0179-0096 |
| Labeler Name: | KAISER FOUNDATION HOSPITALS |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020705 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20110706 |
| Package NDC: | 0179-0096-70 |
| Package Description: | 30 TABLET in 1 BOX, UNIT-DOSE (0179-0096-70) |
| NDC Code | 0179-0096-70 |
| Proprietary Name | RESCRIPTOR |
| Package Description | 30 TABLET in 1 BOX, UNIT-DOSE (0179-0096-70) |
| Product NDC | 0179-0096 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | delavirdine mesylate |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20110706 |
| Marketing Category Name | NDA |
| Labeler Name | KAISER FOUNDATION HOSPITALS |
| Substance Name | DELAVIRDINE MESYLATE |
| Strength Number | 200 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] |